



**Voxzogo (vosoritide)**  
**Prior Authorization Request Form**  
 Caterpillar Prescription Drug Benefit  
 Phone: 877-228-7909 Fax: 800-424-7640



**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

**URGENT**

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE    FEMALE   HEIGHT (IN/CM): \_\_\_\_\_   WEIGHT (LB/KG): \_\_\_\_\_   ALLERGIES: \_\_\_\_\_

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI\\_DISCLOSURE\\_AUTHORIZATION.PDF](https://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): \_\_\_\_\_  
 AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: \_\_\_\_\_

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY <input type="checkbox"/> RENEWAL		IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

*Continued on next page.*





**Voxzogo (vosoritide)**  
**Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit  
 Phone: 877-228-7909 Fax: 800-424-7640



MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
<input type="checkbox"/> Achondroplasia <input type="checkbox"/> Other diagnosis: _____ ICD-10 _____		
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
<p>Is this medication being used in conjunction with a clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Have other causes of achondroplasia or short stature have been ruled out (e.g., malnutrition, hypothyroidism, hypocortisolism, hypochondroplasia, thanatophoric dysplasia, SADDAN syndrome, homozygous achondroplasia)?  <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide chart note and lab documentation</i></p> <p>Does patient have closure of epiphyses? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide chart note documentation</i></p> <p>Will patient's body weight, growth, and physical development will be measured at baseline and monitored throughout therapy?  <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide chart note documentation and dates</i></p> <p>Will Voxzogo be used in combination with growth hormone (i.e., somatropin), or growth hormone analogs (e.g., somapacitan) or insulin-like growth factor (IGF-1) (i.e., mecasermin)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does the patient have an estimated glomerular filtration rate (eGFR) <math>\geq</math> 60 mL/min? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide lab documentation</i></p> <p>Does the patient have clinical and radiographic features consistent with the disorder OR identification of a heterozygous pathogenic variant in the FGFR3 gene (e.g., 1138G&gt;A and 1138G&gt;C by molecular genetic testing)?  <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide chart note and scan documentation</i></p> <p>Has patient had (i.e., within the previous 18 months) or will they receive limb-lengthening surgery? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>For renewal, please answer the following questions:          Is the patient free of unacceptable toxicity from the requested medication? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does the patient have closure of epiphyses or decreased growth velocity (&lt; 1.5 cm/year) in the prior 6 - 12 months?  <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide chart note dates and scan documentation</i></p> <p>Has the patient shown improvement in growth velocity compared to pre-treatment baseline, and improvement in height compared to last measurement that must be within the last 6 months?  <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide chart note dates and documentation</i></p>		





**Voxzogo (vosoritide)**  
**Prior Authorization Request Form**  
 Caterpillar Prescription Drug Benefit  
 Phone: 877-228-7909 Fax: 800-424-7640



**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

---



---

**Please note:** Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

**ATTESTATION:** I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature or Electronic I.D. Verification:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

**FAX THIS FORM TO: 800-424-7640**

**MAIL REQUESTS TO:** Magellan Rx Management Prior Authorization Program; c/o Magellan Health, Inc.  
 4801 E. Washington Street, Phoenix, AZ 85034  
 Phone: 877-228-7909

